Hikma Pharmaceuticals’ (HIK) “Hold” Rating Reaffirmed at Berenberg Bank

Berenberg Bank reiterated their hold rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report released on Thursday, Digital Look reports. The brokerage currently has a GBX 2,000 ($24.70) target price on the stock.

Separately, Barclays restated an equal weight rating and set a GBX 2,000 ($24.70) price target on shares of Hikma Pharmaceuticals in a research report on Monday, April 8th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Hikma Pharmaceuticals currently has an average rating of Moderate Buy and an average price target of GBX 2,068.75 ($25.55).

Hikma Pharmaceuticals Trading Up 2.6 %

Shares of HIK opened at GBX 1,902 ($23.49) on Thursday. Hikma Pharmaceuticals has a 52-week low of GBX 1,711 ($21.13) and a 52-week high of GBX 2,222 ($27.45). The stock has a market cap of £4.22 billion, a PE ratio of 2,840.30, a price-to-earnings-growth ratio of 2.38 and a beta of 0.45. The firm’s fifty day moving average is GBX 1,888.99 and its two-hundred day moving average is GBX 1,870.84. The company has a quick ratio of 1.27, a current ratio of 1.57 and a debt-to-equity ratio of 53.92.

Hikma Pharmaceuticals Increases Dividend

The business also recently announced a dividend, which will be paid on Friday, May 3rd. Shareholders of record on Thursday, March 21st will be issued a $0.47 dividend. This is a boost from Hikma Pharmaceuticals’s previous dividend of $0.25. This represents a yield of 1.86%. The ex-dividend date is Thursday, March 21st. Hikma Pharmaceuticals’s dividend payout ratio is presently 8,507.46%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.